# Reckitt Benckiser Group Continued momentum under RB 2.0

- Link: https://www.directorstalkinterviews.com/reckitt-benckiser-group-continued-momentum-under-rb-2-0/412760589
- Published: 2018-10-30T07:57:34+00:00
- Author: Charlotte Edwards

**Reckitt Benckiser Group** (LON:RB.), today announced results for Q8 2018 trading
update.

  |

 |

Q3

  |

YTD 2018

 

  |  
 |

 |

£m

  |

LFL^(1)

  |

Reported

  |

£m

  |

Pro-forma^(1)

 

  |

LFL^(1)

  |

Reported

 

  |  
 |

IFCN

  |

659

  |

-6%

  |

-8%

  |

2,100

  |

+3%

  |

-5%

  |

n/m

  |  
 |

Rest of Health

  |

1,232

  |

+4%

  |

0%

  |

3,594

  |

+2%

  |

+2%

  |

-3%

  |  
 |

Total Health

 

  |

1,891

  |

0%

  |

-3%

  |

5,694

  |

+3%

  |

+1%

  |

+25%

  |  
 |

Hygiene Home

 

  |

1,229

  |

+4%

  |

0%

  |

3,564

  |

+4%

  |

+4%

  |

-2%

  |  
 |

Total

  |

3,120

  |

+2%

  |

-2%

  |

9,258

  |

+3%

  |

+2%

  |

+13%

  |

 

**Highlights**

· LFL growth in Q3 of +2%. Continued momentum under RB 2.0, with growth in base 
Health and Hygiene Home businesses of +4% LFL. Total growth was negatively impacted
by -2% (£70m) from a temporary manufacturing disruption at our European IFCN plant.

· LFL performance in Total Health was flat, comprising IFCN of -6% and Rest of Health
of +4% driven by continued strong growth in OTC and improving trends in Wellness
and Health Hygiene brands.

· LFL growth in Hygiene Home of +4%. Continued momentum with strong performances
from Finish, Air Wick and Lysol in ENA and Harpic in DvM.

· We remain on track for the full year net revenue target of +14-15% (total constant),
implying LFL revenue growth at the upper end of +2-3%.

> **Commenting on these results, Rakesh Kapoor, Chief Executive Officer of Reckitt
> Benckiser, said:**
> “Q3 was another quarter of progress, with continued momentum and growth under 
> our new RB 2.0 organisational structure. Our base Health and Hygiene Home businesses
> each delivered +4% LFL growth in the quarter, against a backdrop of mixed market
> conditions, demonstrating the strength of our brands, innovation success and early
> signs of RB 2.0 benefits. Although encouraging, we remain focused on further improving
> our growth trajectory.
> Our IFCN business delivered a strong performance in North America, with the launch
> of our recent innovation, Enfamil NeuroPro, and progress in new channels. We also
> remain firmly on track to deliver the medium-term targets we communicated at the
> time of the MJN acquisition.
> The quarter was impacted by a temporary manufacturing disruption at our European
> IFCN plant. This affected sales to a number of markets, occurred during a period
> of unusually high market growth and before our new facilities in Australia were
> operational and able to diversify our supply chain. The disruption was resolved
> and supply restored before the end of the quarter, although we do expect some 
> residual impact in Q4 and into 2019.
> We have sufficient momentum and progress in our business to absorb this temporary
> manufacturing disruption. We therefore reiterate our 2018 target of +14-15% total
> net revenue growth at constant rates.”

 

Share on:
